mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.099 |
0.01 |
mRNA |
Bortezomib |
gCSI |
pan-cancer |
AAC |
-0.15 |
0.01 |
mRNA |
C6-ceramide |
CTRPv2 |
pan-cancer |
AAC |
0.095 |
0.01 |
mRNA |
Nilotinib |
CCLE |
pan-cancer |
AAC |
-0.12 |
0.01 |
mRNA |
NVP-BSK805 |
CTRPv2 |
pan-cancer |
AAC |
0.083 |
0.02 |
mRNA |
BRD9876:MK-1775 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.3 |
0.02 |
mRNA |
GDC-0941 |
CTRPv2 |
pan-cancer |
AAC |
0.086 |
0.02 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.08 |
0.02 |
mRNA |
BRD-A94377914 |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.02 |
mRNA |
piperlongumine:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.083 |
0.02 |